Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beyondspring Inc

1.60
-0.0407-2.48%
Post-market: 1.600.00000.00%16:24 EDT
Volume:8.99K
Turnover:14.47K
Market Cap:64.51M
PE:-5.72
High:1.64
Open:1.64
Low:1.60
Close:1.64
Loading ...

Company Profile

Company Name:
Beyondspring Inc
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
40
Office Location:
100 Campus Drive,4th Floor, Suite 410,West Side,Florham Park,New Jersey,United States
Zip Code:
07932
Fax:
- -
Introduction:
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Directors

Name
Position
Lan Huang
Co-Founder, Chairperson and Chief Executive Officer
Brendan Delaney
Director
Jiangwen Majeti
Director
Matthew Kirkby
Director
Patrick Fabbio
Director
Sihai Xu
Director

Shareholders

Name
Position
Lan Huang
Co-Founder, Chairperson and Chief Executive Officer
June Lu
Chief Scientific Officer